̽��ֱ��

A number of academics, staff and an undergraduate student at the ̽��ֱ�� of Cambridge feature in this year's New Year Honours List, the first of the reign of King Charles III. 

Cambridge scientists have identified a drug that can be repurposed to prevent COVID-19 in research involving a unique mix of ‘mini-organs’, donor organs, animal studies and patients.

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke’s Hospital and the ̽��ֱ�� of Cambridge has found.

Cambridge scientists have used synthetic biology to create artificial enzymes programmed to target the genetic code of SARS-CoV-2 and destroy the virus, an approach that could be used to develop a new generation of antiviral drugs.

Cambridge is among 12 institutions across the UK that will be working together to tackle the monkeypox outbreak, developing better diagnostic tests, identifying potential therapies and studying vaccine effectiveness and the virus’ spread.

Referrals to Cambridge’s long COVID clinic fell dramatically in the period August 2021 to June 2022, which researchers say is likely due to the successful rollout of the vaccine.

A new report highlights the advances and challenges in prevention, clinical care, and research in traumatic brain injury, a leading cause of injury-related death and disability worldwide.

Researchers have been able to alter the blood type of deceased donor kidneys using “molecular scissors”.

A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.

Five Cambridge researchers join the community of more than 1,900 leading life scientists in Europe and beyond today as the European Molecular Biology Organisation announces its newly-elected Members.